Compare HWBK & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HWBK | ENLV |
|---|---|---|
| Founded | 1865 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.3M | 258.7M |
| IPO Year | 1996 | 2014 |
| Metric | HWBK | ENLV |
|---|---|---|
| Price | $33.68 | $0.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 6.1K | ★ 680.2K |
| Earning Date | 04-29-2026 | 05-29-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 31.42 | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $0.66 |
| 52 Week High | $36.25 | $2.10 |
| Indicator | HWBK | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 46.08 |
| Support Level | $33.28 | $0.81 |
| Resistance Level | $35.88 | $1.19 |
| Average True Range (ATR) | 1.07 | 0.10 |
| MACD | 0.18 | -0.01 |
| Stochastic Oscillator | 83.13 | 26.28 |
Hawthorn Bancshares Inc is a financial holding company that, along with its subsidiary bank, provides commercial banking for small and mid-sized businesses, including equipment, operating, commercial real estate and SBA loans, and personal banking services such as real estate mortgage lending, installment and consumer loans, certificates of deposit, checking, savings and money market accounts. The company also provides trust services including estate planning, investment and asset management services, brokerage and cash management services. Its primary source of revenue is net interest income derived from lending and deposit taking activities, with much of its business in commercial, commercial real estate development and residential mortgage lending.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.